All In Biotech

NDA 214520 · Cormedix

Defencath

Heparin Sodium, Taurolidine · N/A · Anti-coagulant; Unfractionated Heparin

NovelPriority review

CDER novel approval, Nov 15, 2023: To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Nov 15, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,126

334 Phase 3, 112 recruiting

FAERS reports

10

4 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2026.

LIMITED POPULATION: DEFENCATH ® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14) ]. Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC. LIMITED POPULATION: DEFENCATH is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients. ( 1 ) Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC. ( 1 )

Mechanism: Heparin Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not...

Therapeutic areas: Infectious disease and vaccines · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 15, 2023 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
2 products under this application
  • DEFENCATH · HEPARIN SODIUM 5,000 UNITS/5ML (1,000 UNITS/ML); TAUROLIDINE 67.5MG/5ML (13.5MG/ML) · SOLUTION, N/A · Prescription
  • DEFENCATH · HEPARIN SODIUM 3,000 UNITS/3ML (1,000 UNITS/ML); TAUROLIDINE 40.5MG/3ML (13.5MG/ML) · SOLUTION, N/A · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Heparin" as an intervention, any sponsor and status, largest first.

All 1,126 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device malfunction4
  • drug hypersensitivity3
  • complication associated with device1
  • device occlusion1
  • dialysis1
  • drug ineffective1
  • fall1
  • hypoxia1
  • infusion related reaction1
  • mental status changes1
  • occupational exposure to product1
  • panic attack1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20241
20252
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,572 on PubMed

Sponsor: Cormedix

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.